PRESS RELEASE published on 01/09/2025 at 01:00, 1 year 7 months ago Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options Onco-Innovations Limited announces exclusive-licensed PNKP inhibitors Technology targeting cancer cells to enhance treatment effectiveness across various cancer types including colorectal, breast, and lung cancer Clinical Trials Cancer Treatment Oncology Market Onco-Innovations Limited PNKP Inhibitors Technology
Published on 08/20/2026 at 00:40, 1 hour 31 minutes ago Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
Published on 08/19/2026 at 22:00, 4 hours 11 minutes ago Jaguar Health Reports Second Quarter 2026 Financials
Published on 08/19/2026 at 20:35, 5 hours 36 minutes ago Revive Therapeutics Announces Proposed Shares for Debt Settlement
Published on 08/19/2026 at 18:50, 7 hours 21 minutes ago AmeriTrust Auto Advances End-to-End Lease Remarketing Strategy
Published on 08/20/2026 at 01:45, 25 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 Annual results – Delivers on guidance and progresses key strategic actions
Published on 08/18/2026 at 18:00, 1 day 8 hours ago KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 1 day 8 hours ago Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 1 day 14 hours ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 1 day 14 hours ago GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 2 days 6 hours ago Aéroports de Paris S.A - July 2026 traffic figures
